Increased understanding of disease mechanisms powers discovery towards targeted therapeutics
We can help you take advantage of these new opportunities and maximize your chances of success in trials with intelligence to make early, informed decisions.
Increase disease understanding and target ID
There’s a vast amount of genomic, biomarker, and compounds effect information available to research scientists – more than we’ve ever seen before. New and innovative solutions are now available to help you pick the best targets from all this data.
Improve success rates in picking the right targets, gain greater insight into disease understanding, and better leverage the vast amount of data to accelerate your scientific discovery. Manage your data and get testable hypotheses for disease mechanisms and subtypes, patient subpopulations, drug targets, biomarkers, treatment effect, and drug repositioning candidates through bioinformatics analysis and data & knowledge management.
Set the right R&D direction early
The new wealth of disease understanding opens up avenues of discovery previously closed off to R&D. A double-edged sword if ever there was one. So when it comes to deciding where to put your resources, you need early intelligence on competitors, targets, approvals, generics, IP, and new markets.
Discover how we can help you to assess the scientific landscape and organize latest published scientific research worldwide.
As you build your R&D strategy, we can help you to closely monitor your competitors, understand target landscapes and stay informed on the latest news in your industry.
Accelerate translational science
Data from the Centers for Medical Research (CMR) shows that fewer than 1 out of every ten drugs that enter clinical trials makes it to market. Improving this ratio by a small amount early on can result in higher likelihood of translation into the clinic, offering a huge impact on returns.
See how we can help you quickly identify and prioritize new targets as well as validate, develop and benchmark therapeutically differentiated treatments with a higher degree of success.
Improve clinical ROI
Patient stratification, disease understanding, and drug action knowledge are continuing to progress, bringing us closer to a world of personalized medicine. At the same time, clinical trials remain an expensive necessity. It is fast becoming an imperative to decide early which treatments offer the best opportunities and focus resources and investment on these.
We can help you design your clinical development program strategically, ensuring your drug’s favorable positioning against the competition.
Within a couple of hours we can now identify targets that we previously hadn’t considered.
A computational drug development team in a top 5 pharma company